EQUITY ALERT: Rosen Law Firm Announces Filing of Securities

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
213
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Tempur Sealy International, Inc. - TPX

NEW YORK, April 14, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Tempur Sealy International, Inc. securities (NYSE: TPX ) from July 28, 2016 through January 27, 2017, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Tempur Sealy investors under the federal securities laws.

To join the Tempur Sealy class action, go to  http://www.rosenlegal.com/cases-1092.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email  pkim@rosenlegal.com  or  kchan@rosenlegal.com  for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Tempur Sealy’s largest customer, Mattress Firm Holding Corp. (“Mattress Firm”), had been engaged in active negotiations to be acquired, which was reasonably likely to have a material adverse effect in Tempur Sealy’s 2016 third and fourth quarter operating results; (2) Tempur Sealy was engaged in active discussions with Mattress Firm concerning modifications to their long-term supply agreements; (3) Mattress Firm had been seeking significant economic concessions from Tempur Sealy; (4) defendants lacked a reasonable basis for Tempur Sealy’s positive statements about Mattress Firm; and (5) as a result, defendants lacked a reasonable basis for their positive statements about Tempur Sealy’s business and future financial prospects. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 23, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1092.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com .

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm .

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 lrosen@rosenlegal.com pkim@rosenlegal.com kchan@rosenlegal.com www.rosenlegal.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 4

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 4

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 7

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 4

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 3

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 4

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading

Top 5 Most Recently Viewed Articles

Vaccinex Unveils Efficacy Insights for Pepinemab in Alzheimer’s Study

Updated Category News Views 71

Vaccinex Provides Update on Pepinemab Study for Alzheimer’s Disease ROCHESTER, N.Y. — Vaccinex, Inc. (NASDAQ: VCNX), a forward-thinking biotechnology firm, is making significant strides in the treatment of Alzheimer's disease (AD) and cancer. The company is focused on a unique approach through the inhibition of Semaphorin 4D (SEMA4D). Recently, it was announced that...

Continue Reading
Legal Inquiry into Netflix, Inc. (NFLX) Attracts Investor Attention

Updated Category News Views 287

Understanding the Investigation into Netflix, Inc. Recently, the law firm Robbins Geller Rudman & Dowd LLP has initiated a formal investigation into Netflix, Inc. (NASDAQ: NFLX). This inquiry primarily focuses on potential violations of U.S. federal securities laws that may have occurred within the company. The Implications for Investors This investigation comes at a...

Continue Reading
Norway's Wealth Fund Expands Portfolio with London Investment

Updated Category News Views 221

Norway's Sovereign Wealth Fund Takes Bold Step in London Norway's sovereign wealth fund, expertly managed by Norges Bank Investment Management, has recently made headlines with its strategic acquisition of a 25% stake in a notable portfolio of office and retail properties located in London's prestigious Mayfair district. Significant Investment in a Prime Location This...

Continue Reading
Exagen Inc. Announces New Biomarkers and Financial Success

Updated Category News Views 291

Exagen Inc. Introduces Groundbreaking Biomarkers for Autoimmune Diseases Innovative testing aims to enhance patient diagnosis and care Exagen Inc. (Nasdaq: XGN), a pioneering company in autoimmune testing, has achieved a significant milestone by receiving conditional approval from the New York State Department of Health for its advanced assays to diagnose systemic lupus...

Continue Reading
Pacaso's Financial Growth in 2025: A Closer Look At Results

Updated Category News Views 1306

Pacaso Shows Promising First Half Financial Performance Pacaso, the innovative platform for co-owned luxury vacation homes, has recently shared its financial results for the first half of 2025, demonstrating strong stability and improved efficiency despite a challenging broader housing market. The company reported an impressive adjusted gross profit while managing to...

Continue Reading